# Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia

> **NCT02110394** · — · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 190 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **OTHER:** bendamustine
- **OTHER:** rituximab

## Key facts

- **NCT ID:** NCT02110394
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2016-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110394, "Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02110394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*